Alkermes PLC (NASDAQ:ALKS) SVP Michael J. Landine sold 15,000 shares of Alkermes PLC stock in a transaction on Wednesday, November 1st. The shares were sold at an average price of $48.71, for a total transaction of $730,650.00. Following the completion of the sale, the senior vice president now directly owns 178,693 shares of the company’s stock, valued at approximately $8,704,136.03. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website.

Alkermes PLC (ALKS) traded up $2.34 during midday trading on Friday, hitting $50.99. The stock had a trading volume of 896,105 shares, compared to its average volume of 971,668.

Alkermes PLC (NASDAQ:ALKS) last released its earnings results on Thursday, October 26th. The company reported $0.03 EPS for the quarter, topping the Zacks’ consensus estimate of ($0.01) by $0.04. The company had revenue of $217.40 million for the quarter, compared to analysts’ expectations of $231.29 million. Alkermes PLC had a negative return on equity of 7.27% and a negative net margin of 20.12%. The business’s revenue for the quarter was up 20.6% compared to the same quarter last year. During the same period in the previous year, the business posted ($0.09) EPS. equities analysts expect that Alkermes PLC will post -0.59 EPS for the current year.

TRADEMARK VIOLATION NOTICE: “Alkermes PLC (ALKS) SVP Michael J. Landine Sells 15,000 Shares” was first posted by American Banking News and is the sole property of of American Banking News. If you are viewing this report on another publication, it was stolen and reposted in violation of international trademark & copyright legislation. The correct version of this report can be viewed at https://www.americanbankingnews.com/2017/11/03/alkermes-plc-alks-svp-michael-j-landine-sells-15000-shares.html.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Toronto Dominion Bank raised its stake in shares of Alkermes PLC by 12.7% during the 2nd quarter. Toronto Dominion Bank now owns 1,875 shares of the company’s stock worth $109,000 after purchasing an additional 212 shares during the period. Daiwa SB Investments Ltd. bought a new stake in shares of Alkermes PLC during the 2nd quarter worth $166,000. Greenwood Capital Associates LLC raised its stake in shares of Alkermes PLC by 1.1% during the 2nd quarter. Greenwood Capital Associates LLC now owns 3,770 shares of the company’s stock worth $219,000 after purchasing an additional 41 shares during the period. US Bancorp DE raised its stake in shares of Alkermes PLC by 366.4% during the 2nd quarter. US Bancorp DE now owns 3,974 shares of the company’s stock worth $231,000 after purchasing an additional 3,122 shares during the period. Finally, Insight Capital Research & Management Inc. purchased a new stake in Alkermes PLC in the 2nd quarter worth about $232,000. Institutional investors own 98.74% of the company’s stock.

Several brokerages have weighed in on ALKS. ValuEngine cut Alkermes PLC from a “hold” rating to a “sell” rating in a research note on Thursday, July 27th. Barclays PLC set a $50.00 price objective on Alkermes PLC and gave the company a “hold” rating in a research note on Thursday, October 26th. Citigroup Inc. set a $62.00 price objective on Alkermes PLC and gave the company a “hold” rating in a research note on Thursday, October 26th. Credit Suisse Group dropped their price objective on Alkermes PLC from $70.00 to $66.00 and set an “outperform” rating on the stock in a research note on Friday, October 27th. Finally, Zacks Investment Research upgraded Alkermes PLC from a “sell” rating to a “hold” rating in a research note on Wednesday, August 2nd. Two equities research analysts have rated the stock with a sell rating, seven have issued a hold rating and five have given a buy rating to the company’s stock. The company presently has an average rating of “Hold” and an average target price of $63.55.

Alkermes PLC Company Profile

Alkermes plc is a biopharmaceutical company. The Company is engaged in the researching, developing and commercializing pharmaceutical products that are designed to address medical needs of patients in therapeutic areas. The Company has a portfolio of marketed drug products and a clinical pipeline of products that address central nervous system (CNS) disorders, such as schizophrenia, depression, addiction and multiple sclerosis (MS).

Insider Buying and Selling by Quarter for Alkermes PLC (NASDAQ:ALKS)

Receive News & Ratings for Alkermes PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alkermes PLC and related companies with MarketBeat.com's FREE daily email newsletter.